Company news
Bioatla, Inc. (NASDAQ:BCAB) news
Bioatla, Inc. news releases on 6ix. Latest, May 18, 2026: Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Press releases & updates
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
May 17, 2026
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
March 30, 2026
BioAtla Announces Share Consolidation
March 30, 2026
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
March 2, 2026
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
December 31, 2025
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
November 21, 2025
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
November 13, 2025
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
November 7, 2025
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
November 5, 2025
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
October 23, 2025
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
October 19, 2025
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
October 3, 2025
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
September 8, 2025
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
August 7, 2025
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
August 4, 2025
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
July 17, 2025
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
July 3, 2025
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Ga...
July 2, 2025
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
June 2, 2025
BioAtla : Earnings Release (bioatla reports first quarter 2025 financial results and)
May 7, 2025
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
May 6, 2025
BioAtla to Participate in the Citizens Life Sciences Conference
April 30, 2025
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
April 29, 2025
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 24, 2025
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2025
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
March 27, 2025
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
March 20, 2025
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
March 19, 2025
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
December 19, 2024
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
December 15, 2024
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
December 9, 2024
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
November 6, 2024
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
October 30, 2024
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
October 3, 2024
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
September 30, 2024
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
September 22, 2024
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European...
September 15, 2024
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
September 8, 2024
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
August 7, 2024
BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024
July 31, 2024
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
July 24, 2024
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
July 22, 2024
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
June 26, 2024
BioAtla to Participate in the Jefferies Global Healthcare Conference
May 28, 2024
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2024
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
May 13, 2024
BioAtla to Participate in the Citizens JMP Life Sciences Conference
May 7, 2024
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
May 6, 2024
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
May 5, 2024